2021年10月13日简报:新冠疫苗可将住院风险降低九成;中国疫苗最快年底获欧盟批准!美FDA拒绝推荐Moderna新冠疫苗作为加强针;

2021-10-13 MedSci整理 MedSci整理

截至北京时间2021年10月13日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过2亿3939万例,新增356,863例,达到239,399,

截至北京时间2021年10月13日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎COVID-19)病例超过2亿3939万例,新增356,863例,达到239,399,191例。累计死亡病例487.9万例,达到4,879,244例。新增死亡为6,209例。康复为216,651,496例,重症和危重症病人达到81,370例;全球新冠确诊病例超过100万例的国家达35个,110个国家病例超10万例。昨日报道:2021年10月12日简报:灭活疫苗接种后、以mRNA疫苗加强接种,中和抗体提升46.6倍;日本新冠疫情“退潮”令专家困惑;全国累计报告接种新冠疫苗22.2亿剂次

全国10余省份开打疫苗加强免疫接种

今年9月,浙江、河南等地就提出启动新冠病毒疫苗加强免疫接种工作。截至目前,据不完全统计,安徽、福建、河南、黑龙江、湖北等10余省份已明确启动加强针接种。

FDA专家称两剂新冠疫苗足以预防重症和死亡

周二,美国食品和药物管理局(FDA)拒绝就是否批准Moderna(MRNA.US)新冠疫苗加强针接种表达立场。该局的科学家称,数据显示,两剂疫苗仍足以在美国预防重症和死亡。

在FDA网站上发布的一份文件显示:“一些针对实际情况做出的有效性研究表明,随着时间的推移,Moderna疫苗对无症状的感染或对德尔塔变种的有效性正在下降,而其他的研究并没有显示出这样的结论。然而,总体而言,数据表明,目前美国许可或授权的新冠疫苗仍可在美国预防重症和死亡。”

FDA工作人员也没有对辉瑞(PFE.US)上月的新冠疫苗加强针进行表态。但这并没有阻止该机构的疫苗和相关生物产品咨询委员会建议注射第三针。

委员会拒绝了辉瑞公司最初提议的、向所有16岁及以上的人接种加强针的计划,将其接种范围缩小到新冠感染风险最高的人群,包括老年人和有其它健康问题的人。FDA官员后来扩大了符合条件的人群,包括那些在高风险环境下工作或生活的人,比如医疗保健和杂货店的工作人员。

FDA科学家的这份报告旨在向委员会汇报情况。委员会将于周四召开会议,审议Moderna提出的授权疫苗加强针的请求。从公布的文件中可以看出该机构对第三针的看法。

9月1日,Moderna向FDA申请了加强针的授权。公司表示,第三针注射的剂量只有前两次注射剂量的一半,是安全的,而且产生的免疫反应比第三阶段临床试验中第二次注射后更强。

截至10月9日上周六,已有超过700万美国人接种了新冠疫苗加强针。曾有FDA与CDC的官员认为,如果只批准辉瑞疫苗加强针,将令上千万已经接种Moderna或强生疫苗的美国人排除在更强效的保护之外。

新冠疫苗可将住院风险降低九成

法国医疗保险局和法国国家药品安全管理局组成的科学研究团队Epi-Phare研究人员比较了从2020年12月27日至2021年7月20日,法国约1100万名50岁以上新冠疫苗接种者和约1100万名同龄未接种新冠疫苗人员的数据。结果显示,从注射第二剂新冠疫苗后的第14天开始,接种者住院和死亡的风险降低90%,而且这种疗效没有在随后的五个月内降低。这些数据与以色列、英国、美国等其它一些国家的研究结果一致。

该研究团队负责人、流行病学家马哈茂德·祖雷克表示,这是迄今为止全球范围内最大规模的新冠疫苗有效性研究。研究结果意味着,接种者因新冠感染而住院或死亡的风险仅为未接种人员的九分之一。

另一方面,接种新冠疫苗似乎对“德尔塔”变异株也同样有效,“德尔塔”变异株在法国占主导地位期间,相关数据接近此前数据:对75岁及以上年龄组的有效性为84%,对50岁至74岁年龄组的有效性超过92%。但祖雷克表示,由于研究时间非常短,无法准确评估接种新冠疫苗对“德尔塔”变异株的实际防护效果,因此这项研究将继续进行。

中国疫苗最快年底获欧盟批准! 

欧洲药品管理局预计将在年底前决定是否再批准四种新型新冠疫苗——包括中国和俄罗斯制造的疫苗,该机构疫苗战略负责人卡瓦莱里说,与中国和俄罗斯疫苗生产商的沟通是“建设性的”,但还需要更多的数据。

英国政府目前认可在欧洲和美国接种的两剂疫苗,即认可美国食品和药物管理局和欧洲药品管理局所批准使用的疫苗。

这意味,一旦欧盟批准,中国疫苗也将获得英国认可,如果按英媒报道,英国下月取消琥珀灯、绿灯国名单,改之以疫苗接种状态而决定入境者是否隔离或测试,中国大陆接种两剂中国疫苗者在疫苗获得英国认可后,进入英国后将免除隔离甚至免测试。

《泰晤士报》报道,作为英国入境新政的一部分,英国政府计划考虑取消对接种两剂疫苗(英国认可的类型)的入境旅客进行测试的要求,不过来自红色国家的除外。申根签证官网显示,目前,部分欧盟/申根国家认可中国疫苗作为入境免疫证明。

其中认可中国国药疫苗的有:奥地利、塞浦路斯、希腊、匈牙利、冰岛、荷兰、西班牙、瑞典、芬兰、瑞士、塞尔维亚、黑山、北马其顿等。

认可科兴疫苗的有:奥地利、塞浦路斯、芬兰、希腊、冰岛、荷兰、西班牙、瑞典、瑞士、塞尔维亚、阿尔巴尼亚、北马其顿等。

爱尔兰,决定从10月22日起全面放开

爱尔兰近期宣布,将从10月22日起全面放开。放宽限制的具体计划从9月持续到10月,包括允许恢复圣餐和坚信礼,宾果游戏厅、保龄球馆、室内运动,舞蹈和其他课程将于9月20日回归,夜总会也会重新开放。

爱尔兰曾是欧洲封锁时间最长的国家之一,现在是欧洲推行接种新冠疫苖最成功的国家之一,总比例达到70%。其中成人接种率超过90%,12岁以上人群接种率超过80%。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2008803, encodeId=06d5200880307, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Oct 15 12:09:12 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820735, encodeId=ba4b1820e3508, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Jan 21 12:09:12 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251742, encodeId=6ec41251e425a, content=<a href='/topic/show?id=fab72646628' target=_blank style='color:#2F92EE;'>#住院风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26466, encryptionId=fab72646628, topicName=住院风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Thu Oct 14 22:09:12 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590045, encodeId=3eed159004506, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Thu Oct 14 22:09:12 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060075, encodeId=15d310600e5d9, content=必读且客观, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Wed Oct 13 10:56:52 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060036, encodeId=5b0110600369f, content=每日必读, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Wed Oct 13 08:43:16 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060043, encodeId=5973106004336, content=FDA部分有点机翻, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=039f5540663, createdName=cheng166, createdTime=Wed Oct 13 09:10:39 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060031, encodeId=5d961060031b1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210425/ba9e2f26f7a140dbb2d6a40400bb3161/a8e9daa225944f2bbf06af54e002d812.jpg, createdBy=bc105244563, createdName=侯月辉, createdTime=Wed Oct 13 08:16:42 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-10-15 般若傻瓜
  2. [GetPortalCommentsPageByObjectIdResponse(id=2008803, encodeId=06d5200880307, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Oct 15 12:09:12 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820735, encodeId=ba4b1820e3508, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Jan 21 12:09:12 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251742, encodeId=6ec41251e425a, content=<a href='/topic/show?id=fab72646628' target=_blank style='color:#2F92EE;'>#住院风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26466, encryptionId=fab72646628, topicName=住院风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Thu Oct 14 22:09:12 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590045, encodeId=3eed159004506, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Thu Oct 14 22:09:12 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060075, encodeId=15d310600e5d9, content=必读且客观, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Wed Oct 13 10:56:52 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060036, encodeId=5b0110600369f, content=每日必读, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Wed Oct 13 08:43:16 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060043, encodeId=5973106004336, content=FDA部分有点机翻, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=039f5540663, createdName=cheng166, createdTime=Wed Oct 13 09:10:39 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060031, encodeId=5d961060031b1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210425/ba9e2f26f7a140dbb2d6a40400bb3161/a8e9daa225944f2bbf06af54e002d812.jpg, createdBy=bc105244563, createdName=侯月辉, createdTime=Wed Oct 13 08:16:42 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2008803, encodeId=06d5200880307, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Oct 15 12:09:12 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820735, encodeId=ba4b1820e3508, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Jan 21 12:09:12 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251742, encodeId=6ec41251e425a, content=<a href='/topic/show?id=fab72646628' target=_blank style='color:#2F92EE;'>#住院风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26466, encryptionId=fab72646628, topicName=住院风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Thu Oct 14 22:09:12 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590045, encodeId=3eed159004506, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Thu Oct 14 22:09:12 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060075, encodeId=15d310600e5d9, content=必读且客观, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Wed Oct 13 10:56:52 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060036, encodeId=5b0110600369f, content=每日必读, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Wed Oct 13 08:43:16 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060043, encodeId=5973106004336, content=FDA部分有点机翻, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=039f5540663, createdName=cheng166, createdTime=Wed Oct 13 09:10:39 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060031, encodeId=5d961060031b1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210425/ba9e2f26f7a140dbb2d6a40400bb3161/a8e9daa225944f2bbf06af54e002d812.jpg, createdBy=bc105244563, createdName=侯月辉, createdTime=Wed Oct 13 08:16:42 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2008803, encodeId=06d5200880307, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Oct 15 12:09:12 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820735, encodeId=ba4b1820e3508, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Jan 21 12:09:12 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251742, encodeId=6ec41251e425a, content=<a href='/topic/show?id=fab72646628' target=_blank style='color:#2F92EE;'>#住院风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26466, encryptionId=fab72646628, topicName=住院风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Thu Oct 14 22:09:12 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590045, encodeId=3eed159004506, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Thu Oct 14 22:09:12 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060075, encodeId=15d310600e5d9, content=必读且客观, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Wed Oct 13 10:56:52 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060036, encodeId=5b0110600369f, content=每日必读, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Wed Oct 13 08:43:16 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060043, encodeId=5973106004336, content=FDA部分有点机翻, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=039f5540663, createdName=cheng166, createdTime=Wed Oct 13 09:10:39 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060031, encodeId=5d961060031b1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210425/ba9e2f26f7a140dbb2d6a40400bb3161/a8e9daa225944f2bbf06af54e002d812.jpg, createdBy=bc105244563, createdName=侯月辉, createdTime=Wed Oct 13 08:16:42 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2008803, encodeId=06d5200880307, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Oct 15 12:09:12 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820735, encodeId=ba4b1820e3508, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Jan 21 12:09:12 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251742, encodeId=6ec41251e425a, content=<a href='/topic/show?id=fab72646628' target=_blank style='color:#2F92EE;'>#住院风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26466, encryptionId=fab72646628, topicName=住院风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Thu Oct 14 22:09:12 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590045, encodeId=3eed159004506, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Thu Oct 14 22:09:12 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060075, encodeId=15d310600e5d9, content=必读且客观, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Wed Oct 13 10:56:52 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060036, encodeId=5b0110600369f, content=每日必读, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Wed Oct 13 08:43:16 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060043, encodeId=5973106004336, content=FDA部分有点机翻, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=039f5540663, createdName=cheng166, createdTime=Wed Oct 13 09:10:39 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060031, encodeId=5d961060031b1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210425/ba9e2f26f7a140dbb2d6a40400bb3161/a8e9daa225944f2bbf06af54e002d812.jpg, createdBy=bc105244563, createdName=侯月辉, createdTime=Wed Oct 13 08:16:42 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-10-13 医者仁者

    必读且客观

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2008803, encodeId=06d5200880307, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Oct 15 12:09:12 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820735, encodeId=ba4b1820e3508, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Jan 21 12:09:12 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251742, encodeId=6ec41251e425a, content=<a href='/topic/show?id=fab72646628' target=_blank style='color:#2F92EE;'>#住院风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26466, encryptionId=fab72646628, topicName=住院风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Thu Oct 14 22:09:12 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590045, encodeId=3eed159004506, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Thu Oct 14 22:09:12 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060075, encodeId=15d310600e5d9, content=必读且客观, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Wed Oct 13 10:56:52 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060036, encodeId=5b0110600369f, content=每日必读, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Wed Oct 13 08:43:16 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060043, encodeId=5973106004336, content=FDA部分有点机翻, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=039f5540663, createdName=cheng166, createdTime=Wed Oct 13 09:10:39 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060031, encodeId=5d961060031b1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210425/ba9e2f26f7a140dbb2d6a40400bb3161/a8e9daa225944f2bbf06af54e002d812.jpg, createdBy=bc105244563, createdName=侯月辉, createdTime=Wed Oct 13 08:16:42 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-10-13 DR.Fu SIR

    每日必读

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2008803, encodeId=06d5200880307, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Oct 15 12:09:12 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820735, encodeId=ba4b1820e3508, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Jan 21 12:09:12 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251742, encodeId=6ec41251e425a, content=<a href='/topic/show?id=fab72646628' target=_blank style='color:#2F92EE;'>#住院风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26466, encryptionId=fab72646628, topicName=住院风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Thu Oct 14 22:09:12 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590045, encodeId=3eed159004506, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Thu Oct 14 22:09:12 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060075, encodeId=15d310600e5d9, content=必读且客观, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Wed Oct 13 10:56:52 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060036, encodeId=5b0110600369f, content=每日必读, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Wed Oct 13 08:43:16 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060043, encodeId=5973106004336, content=FDA部分有点机翻, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=039f5540663, createdName=cheng166, createdTime=Wed Oct 13 09:10:39 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060031, encodeId=5d961060031b1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210425/ba9e2f26f7a140dbb2d6a40400bb3161/a8e9daa225944f2bbf06af54e002d812.jpg, createdBy=bc105244563, createdName=侯月辉, createdTime=Wed Oct 13 08:16:42 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-10-13 cheng166

    FDA部分有点机翻

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2008803, encodeId=06d5200880307, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Oct 15 12:09:12 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820735, encodeId=ba4b1820e3508, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Jan 21 12:09:12 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251742, encodeId=6ec41251e425a, content=<a href='/topic/show?id=fab72646628' target=_blank style='color:#2F92EE;'>#住院风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26466, encryptionId=fab72646628, topicName=住院风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Thu Oct 14 22:09:12 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590045, encodeId=3eed159004506, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Thu Oct 14 22:09:12 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060075, encodeId=15d310600e5d9, content=必读且客观, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Wed Oct 13 10:56:52 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060036, encodeId=5b0110600369f, content=每日必读, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Wed Oct 13 08:43:16 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060043, encodeId=5973106004336, content=FDA部分有点机翻, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=039f5540663, createdName=cheng166, createdTime=Wed Oct 13 09:10:39 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060031, encodeId=5d961060031b1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210425/ba9e2f26f7a140dbb2d6a40400bb3161/a8e9daa225944f2bbf06af54e002d812.jpg, createdBy=bc105244563, createdName=侯月辉, createdTime=Wed Oct 13 08:16:42 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-10-13 侯月辉

    学习了

    0

相关资讯

2021年10月5日简报:欧洲药管局批准所有成人打辉瑞加强针;卡塔尔将中国新冠疫苗列入认可疫苗清单;英国进一步简化入境政策

截至北京时间2021年10月5日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过23606万例,新增307,395例,达到236,062,47

2021年10月6日简报:美国民众反智,奇葩新冠阴谋论流行,大批民众拒绝接种疫苗;欧洲药品管理局可能开始加速评估默克的新冠口服药;新西兰宣布放弃“彻底消除新冠”战略

截至北京时间2021年10月6日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过23655万例,新增394,248例,达到236,554,40

mRNA疫苗保护力5个月后大幅降低,首款新冠口服药即将获批:新冠研究新近进展

mRNA疫苗保护力5个月后大幅降低,首款新冠口服药即将获批 | 新冠研究最新进展

2021年10月12日简报:灭活疫苗接种后、以mRNA疫苗加强接种,中和抗体提升46.6倍;日本新冠疫情“退潮”令专家困惑;全国累计报告接种新冠疫苗22.2亿剂次

截至北京时间2021年10月12日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过238971万例,新增295,895例,达到238,971,

Lancet:新冠疫苗BNT162b2预防德尔塔变体感染的有效率高达93%!

BNT162b2 疫苗在完全接种后 6 个月内具有很高的预防新冠肺炎住院的有效率,即使面对 δ 变体的广泛传播

2021年10月7日简报:张文宏认为新冠结束时间已不远!口服药,加强针成为全球重新开放的保障;全球新增新冠确诊病例和死亡人数继续下降

截至北京时间2021年10月7日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过23701万例,新增413,161例,达到237,010,37